A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Subjects With Solid Malignancies
This is a Phase I open-label, multi-center study of GS-9716 tested either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies. Primary objectives are to define the maximum tolerated dose (MTD) or maximum administered dose of GS-9716, and characterize the safety and tolerability of GS-9716 as monotherapy and in combination with anti-cancer therapies.
View MoreAge
18 Years +
Sex
All
Healthy Volunteers
No
Medical Condition
Solid Malignancies
Gender
N/A
Date
September 2021 - January 2027
Study Type
Interventional
Study Phase
Phase 1
Product
GS-9716, Docetaxel, sacituzumab govitecan-hziy
Grand Rapids, Michigan, United States, 49546
Bronx, New York, United States, 10467
Portland, Oregon, United States, 97239
Nashville, Tennessee, United States, 37203
San Antonio, Texas, United States, 78229
West Valley City, Utah, United States, 84119
Haifa, Israel, 31096
Jerusalem, Israel, 91120
Tel Aviv, Israel, 6423906
Share Trial